


# Course Programme & Exhibition Information



## Cancer Imaging and Intervention: a Multidisciplinary Approach

### International Cancer Imaging Society 17<sup>th</sup> Annual Teaching Course

2<sup>nd</sup>-4<sup>th</sup> October 2017

Langenbeck-Virchow Haus, Berlin, Germany

In association with:









DEUTSCHE RÖNTGENGESELLSCHAFT  
Gesellschaft für medizinische Radiologie e.V.

[icimatingsociety.org.uk](http://icimatingsociety.org.uk)

# Contents

- 03 ICIS 2017 Faculty and Judging panels
- 04 Floor plan
- 06 Scientific programme: Monday 2nd October
- 08 Scientific programme: Tuesday 3rd October
- 10 Scientific programme: Wednesday 4th October
- 11 Future meetings
- 12 Scientific paper session
- 13 Scientific poster exhibition
- 16 ICIS 2017 venues (map of Langenbeck-Virchow Haus and the barge Alexander von Humboldt)
- 18 Exhibitors and sponsors
- 25 2017 Social events and sponsor lectures

## Key to Scientific Programme

-  Keynote Lecture
-  Main Lecture Hall Session
-  Robert Koch Session
-  Computer Hands-on Workshop
-  Scientific Papers
-  Break

### Important

Please ensure you complete the electronic feedback survey every afternoon, once all lectures have finished, to ensure receipt of your CPD certificate. Please go to [icimagningsociety.org.uk/survey](http://icimagningsociety.org.uk/survey) and on your last day you will be able to generate your own CPD certificate. Please note you must log on with the email you used to register onto the course.

### ICIS 2017 is accredited by:

European Accreditation Council for CME (EACCME): 16 European CME credits (ECMEC)  
The Royal College of Radiologists: 17 Category 1 (external) CPD credits  
Medical Association Berlin: 16 category B points

Delegates attending a live case workshop will receive 3 category C points  
American delegates can have their EACCME European CME Credits converted to AMA PRA Category 1 Credit™ by applying to the AMA

# Faculty

## ICIS Fellows

- A. Athanasiou (Athens)
- J. Barentsz (Nijmegen)
- M. Bellomi (Milan)
- H. Chandarana (New York)
- C. Collins (Dublin)
- S. Diederich (Düsseldorf)
- M. D'Onofrio (Verona)
- K. Elsayes (Houston)
- R. Forstner (Salzburg)
- I. Francis (Ann Arbor)
- J. Fütterer (Nijmegen)
- B. Gebauer (Berlin)
- R. Gore (Chicago)
- L. Grazioli (Brescia)
- J. Heiken (St Louis)
- R. Hermans (Leuven)
- C. Herold (Vienna)
- K. Jhaveri (Toronto)
- P-L. Khong (Hong Kong)
- A. King (Hong Kong)
- D-M. Koh (London)
- O. Lucidarme (Paris)
- G. Masselli (Rome)
- M. Mayerhöfer (Vienna)
- B. McCarville (Memphis)
- K. McHugh (London)
- T. McLoud (Boston)
- G. Morana (Treviso)
- G. Morana (Genoa)
- M. Oudkerk (Groningen)
- W. Oyen (London)
- A. Padhani (London)
- G. Petralia (Milan)
- L. Quint (Ann Arbor)
- R. Reznek (London)
- A. Rockall (London)
- D. Roebuck (London)
- E. Rummeny (Munich)
- A. Sahdev (London)
- E. Sala (New York)
- W. Schima (Vienna)
- H-P Schlemmer (Heidelberg)
- A. Smets (Amsterdam)
- A. Sohaib (London)
- H. Thoeny (Bern)
- A. Towbin (Cincinnati)
- A. Van den Abbeele (Boston)
- A. Vargas (New York)
- S. Vinnicombe (Dundee)
- R. Vliegthart (Groningen)

## Invited Faculty



- D. Busch (Stralsund)
- F. Collettini (Berlin)
- S. Combs (Munich)
- S. Gatidis (Tübingen)
- A. Giagounidis (Düsseldorf)
- L. Koi (Dresden)
- D. Mönnich (Tübingen)
- C. Rübe (Homburg)
- D. Schnapauff (Berlin)
- D. Wormanns (Berlin)
- D. Zips (Tübingen)

## Scientific Committee and Judges


- Nishat Bharwani (London)
- Rosemarie Forstner (Salzburg)
- Jürgen Fütterer (Nijmegen)
- Ann King (Hong Kong)
- Antonio Luna (Jaén)
- Giuseppe Petralia (Milan)
- Evis Sala (New York)
- Alex Towbin (Cincinnati)
- Alberto Vargas (New York)

# Langenbeck-Virchow Haus Lower Ground Floor

- 1 Guerbet
- 2 Siemens Healthineers
- 3 Medtronic
- 4 Sirtex
- 5 GE Healthcare
- 6 Beckelmann MEDTRON
- 7 Mint Medical
- 8 Bracco
- 9 BioMed Central
- 10 Philips




# 1<sup>st</sup> Floor



Scientific poster exhibition on 4<sup>th</sup> Floor

# 5<sup>th</sup> Floor



# Scientific Programme: Monday 2nd October

TIME	SUBJECT & SPEAKER	VENUE
08:45 - 09:00	<b>Welcome and Presidential Address</b> Stefan Diederich	Main Lecture Hall
09:00 - 10:30	<b>Structured Reporting and Decision Support</b> Andrea Rockall	Main Lecture Hall
09:00 - 09:30	<b>PI-RADS: update 2017</b> - Jelle Barentsz	
09:30 - 10:00	<b>LI-RADS: update 2017</b> - Jay Heiken	
10:00 - 10:30	<b>Met-RADS-P</b> - Anwar Padhani	
09:00 - 10:30	<b>Hands-on-Workshop 1</b>	Bernhard von Langenbeck Room
HS1	<b>Multimodality Imaging of the Breast</b> Sarah Vinnicombe & Alexandra Athanasiou	
09:00 - 10:30	<b>Head and Neck</b> Wim Oyen	Robert Koch Room
09:00 - 09:30	<b>MRI in nasopharyngeal carcinoma</b> - Ann King	
09:30 - 10:00	<b>Perineural spread in head and neck cancer</b> - Robert Hermans	
10:00 - 10:30	<b>Molecular imaging in head and neck cancer</b> - Wim Oyen	
10:30 - 11:00	<b>Refreshment Break</b>	
11:00 - 12:30	<b>Precision Medicine</b> Rodney Reznik	Main Lecture Hall
11:00 - 11:30	<b>Precision medicine – concepts and promises</b> - Aristoteles Giagounidis	
11:30 - 12:00	<b>Multiparametric imaging of tumour biology</b> - Anwar Padhani	
12:00 - 12:30	<b>Tumour heterogeneity: what does it mean?</b> - Dow-Mu Koh	
11:00 - 12:30	<b>Hands-on-Workshop 2</b>	Bernhard von Langenbeck Room
HS2	<b>Multiparametric Imaging of the Prostate</b> Heinz-Peter Schlemmer & Harriet Thoeny	
11:00 - 12:30	<b>Joint with DEGRO: Delineation of Tumour and Normal Tissue</b> Ernst Rummeny & Stephanie Combs	Robert Koch Room
11:00 - 11:30	<b>Dose concepts in radiation therapy</b> - Stephanie Combs	
11:30 - 12:00	<b>Imaging following stereotactic radiotherapy in the liver</b> - Luigi Grazioli	
12:00 - 12:30	<b>Imaging interpretation in the post treatment pelvis</b> - Andrea Rockall	
12:30 - 13:00	<b>Scientific Papers.</b> Please see page 12 for details	
12:30 - 14:00	<b>Lunch</b> Parallel Industry Sponsored Symposia. Please see page 25 for details	

14:00 - 14:30	<b>Keynote Lecture 1</b> Wolfgang Schima	<b>Main Lecture Hall</b>
<b>Cancer Imaging in the era of precision medicine</b> - Annick D. Van den Abbeele		
14:30 - 15:30	<b>Prostate: When to Treat</b> Wim Oyen	<b>Main Lecture Hall</b>
14:30 - 15:00	<b>Early diagnosis of significant cancer – how good is mpMRI?</b> - Jelle Barentsz	
15:00 - 15:30	<b>MRI in active surveillance of prostate cancer</b> - Jurgen Fütterer	
14:00 - 15:30	<b>Hands-on-Workshop 3</b>	<b>Bernhard von Langenbeck Room</b>
HS3	<b>MRI of Ovarian Masses</b> Andrea Rockall & Rosemarie Forstner	
14:00 - 15:30	<b>Interventions: Percutaneous and Intraoperative</b> Ernst Rummeny	<b>Robert Koch Room</b>
14:00 - 14:30	<b>Image-guided thermoablation of liver tumours</b> - Bernhard Gebauer	
14:30 - 15:00	<b>Irreversible electroporation in locally advanced pancreatic cancer</b> - Daniel Busch	
15:00 - 15:30	<b>Response assessment of thermoablation in liver and pancreas</b> - Mirko D'Onofrio	
15:30 - 16:00	<b>Refreshment Break</b>	
16:00 - 17:30	<b>Lung Cancer Update</b> Matthijs Oudkerk	<b>Main Lecture Hall</b>
16:00 - 16:20	<b>8th revision of the TNM staging system</b> - Theresa McCloud	
16:20 - 16:40	<b>Lung cancer screening update</b> - Christian Herold	
16:40 - 17:00	<b>Unusual CT-morphology of early lung cancer</b> - Massimo Bellomi	
17:00 - 17:20	<b>New solid nodules at lung cancer screening</b> - Matthijs Oudkerk	
17:20 - 17:30	<b>Q&amp;A</b>	
16:00 - 17:30	<b>Hands-on-Workshop 4</b>	<b>Bernhard von Langenbeck Room</b>
HS4	<b>Hepatic Lesions</b> Wolfgang Schima & Kartik Jhaveri	
16:00 - 17:30	<b>Joint with DEGRO: Side Effects of Radiation Therapy</b> Stefan Diederich & Christian Rube	<b>Robert Koch Room</b>
16:00 - 16:20	<b>Therapy of side effects: what the radiation oncologist needs to know</b> - Christian Rube	
16:20 - 16:40	<b>Thoracic complications of radiation therapy</b> - Stefan Diederich	
16:40 - 17:00	<b>Abdominal complications of radiation therapy</b> - Richard Gore	
17:00 - 17:20	<b>Imaging of radiation-induced CNS toxicity</b> - Giovanni Morana	
17:20 - 17:30	<b>Q&amp;A</b>	
17:30 - 19:00	<b>Welcome Reception in Foyer</b>	

# Scientific Programme: Tuesday 3rd October

TIME	SUBJECT & SPEAKER	VENUE
08:30 - 09:00	<b>Breakfast Symposium</b> Industry Sponsored Symposium. Please see page 25 for details	
09:00 - 10:30	<b>Response Assessment</b> Conor Collins	Main Lecture Hall
09:00 - 09:30	<b>RECIST – the concept and the challenges</b> - Aslam Sohaib	
09:30 - 10:00	<b>Resisting RECIST – new methods of assessing tumour response</b> - Richard Gore	
10:00 - 10:30	<b>Whole-body imaging for response assessment</b> - Giuseppe Petralia	
09:00 - 10:30	<b>Hands-on-Workshop 5</b>	Bernhard von Langenbeck Room
HS5	<b>Pancreatic Tumours</b> Isaac Francis & Giovanni Morana	
09:00 - 10:30	<b>Joint with ESTRO: MR-Guided Radiation Therapy</b> Stefan Diederich & Daniel Zips	Robert Koch Room
09:00 - 09:30	<b>Introduction, concept and current status</b> - Daniel Zips	
09:30 - 10:00	<b>Challenges for medical physics</b> - David Mönnich	
10:00 - 10:30	<b>Opportunities for diagnostic radiology</b> - Sergios Gatidis	
10:30 - 11:00	<b>Refreshment Break</b>	
11:00 - 11:30	<b>Keynote Lecture 2</b> Wim Oyen	Main Lecture Hall
	<b>Immunotherapy: Imaging Redefined</b> - Bernhard Gebauer	
11:30 - 12:30	<b>Radiogenomics in Female Cancer</b> Andrea Rockall	Main Lecture Hall
11:30 - 12:00	<b>What radiogenomics can do for breast cancer</b> - Sarah Vinnicombe	
12:00 - 12:30	<b>Ovarian cancer: the role of imaging in interrogating tumour biology and genomics</b> - Evis Sala	
11:00 - 12:30	<b>Hands-on-Workshop 6</b>	Bernhard von Langenbeck Room
HS6	<b>Lung Cancer Staging: 8th Edition Update</b> Leslie Quint & Rozemarijn Vliegenthart	
11:00 - 12:30	<b>Joint with DEGRO: Assessing Therapy Response</b> Lydia Koi & Dow-Mu Koh	Robert Koch Room
11:00 - 11:30	<b>Biology of radiation effects</b> - Lydia Koi	
11:30 - 12:00	<b>Response assessment in the pelvis</b> - Aslam Sohaib	
12:00 - 12:30	<b>Imaging features of response in the bones</b> - Dow-Mu Koh	
12:30 - 13:00	<b>Scientific Papers.</b> Please see page 12 for details	
12:30 - 14:00	<b>Lunch</b> Parallel Industry Sponsored Symposia. Please see page 25 for details	



13:45 - 14:00	<b>Gold Medal Presentation</b> Stefan Diederich	Main Lecture Hall
14:00 - 15:30	<b>Update Contrast Media</b> Ernst Rummeny	Main Lecture Hall
14:00 - 14:30	<b>Gadolinium deposition in the brain: so what?</b> - Harriet Thoeny	
14:30 - 15:00	<b>Liver-specific contrast media – when and why</b> - Giovanni Morana	
15:00 - 15:30	<b>Contrast-associated acute kidney injury – evolving concepts</b> - Jay Heiken	
14:00 - 15:30	<b>Hands-on-Workshop 7</b>	Bernhard von Langenbeck Room
HS7	<b>Uterine Cancer</b> Anju Sahdev & Evis Sala	
14:00 - 15:30	<b>Interventions: Percutaneous</b> Bernhard Gebauer	Robert Koch Room
14:00 - 14:30	<b>CT-guided high-dose brachytherapy</b> - Dirk Schnapauff	
14:30 - 15:00	<b>Image-guided interventions in prostate cancer</b> - Jurgen Fütterer	
15:00 - 15:30	<b>Interventional radiology in paediatric oncology</b> - Derek Roebuck	
15:30 - 16:00	<b>Refreshment Break</b>	
16:00 - 17:30	<b>Side Effects of Medical Therapy</b> Rosemarie Forstner	Main Lecture Hall
16:00 - 16:30	<b>Pulmonary complications of molecular targeted therapy</b> - Richard Gore	
16:30 - 17:00	<b>Acute abdominal complications in children</b> - Kieran McHugh	
17:00 - 17:30	<b>How to differentiate between residual disease and treatment complications</b> - Dow-Mu Koh	
16:00 - 17:30	<b>Hands-on-Workshop 8</b>	Bernhard von Langenbeck Room
HS8	<b>Whole Body MRI</b> Giuseppe Petralia & Anwar Padhani	
16:00 - 17:30	<b>Interventions: Vascular</b> Wolfgang Schima	Robert Koch Room
16:00 - 16:30	<b>TACE in metastases and hepatocellular carcinoma</b> - Federico Colletini	
16:30 - 17:00	<b>Radioembolization (SIRT)</b> - Dirk Schnapauff	
17:00 - 17:30	<b>Portal vein embolization</b> - Bernhard Gebauer	
18.30	<b>Course Party on the barge "Alexander von Humboldt"</b> Award of prizes for scientific presentations and posters	

# Scientific Programme: Wednesday 4th October

TIME	SUBJECT & SPEAKER	VENUE
09:00 - 10:30	<b>How to Diagnose Focal Liver Lesions</b> Wolfgang Schima	Main Lecture Hall
09:00 - 09:25	<b>Practical approach to diagnosis of focal hepatic enhancing lesions</b> - Khaled Elsayes	
09:25 - 09:45	<b>Rare and unusual liver tumours</b> - Giovanni Morana	
09:45 - 10:05	<b>How to deal with liver incidentalomas</b> - Jay Heiken	
10:05 - 10:25	<b>MRI of cholangiocarcinoma</b> - Kartik Jhaveri	
10:25 - 10:30	<b>Q&amp;A</b>	
09:00 - 10:30	<b>Female Pelvis</b> Rosemarie Forstner	Robert Koch Room
09:00 - 09:30	<b>Imaging of uterine tumours</b> - Alberto Vargas	
09:30 - 10:00	<b>Incidental adnexal masses</b> - Gabriele Masselli	
10:00 - 10:30	<b>Understanding Female Pelvis spread patterns: can imaging provide a GPS for treatment planning and surgical guidance?</b> - Evis Sala	
09:00 - 10:30	<b>Malignant Lymphoma</b> Conor Collins	Bernhard von Langenbeck Room
09:00 - 09:30	<b>Head and neck lymphoma</b> - Ann King	
09:30 - 10:00	<b>Staging and response assessment in lymphoma</b> - Marius Mayerhöfer	
10:00 - 10:30	<b>Paediatric lymphoma</b> - Pek-Lan Khong	
10:30 - 11:00	<b>Refreshment Break</b>	
11:00 - 12:30	<b>Pancreatic Tumours</b> Giovanni Morana	Main Lecture Hall
11:00 - 11:20	<b>MRI of pancreatic tumours</b> - Kartik Jhaveri	
11:20 - 11:40	<b>Incidental pancreatic cysts – what we know and what we don't know</b> - Jay Heiken	
11:40 - 12:00	<b>IPMN – field defect, precursor lesion or innocent bystander?</b> - Richard Gore	
12:00 - 12:20	<b>Neuroendocrine pancreatic tumours</b> - Isaac Francis	
12:20 - 12:30	<b>Q&amp;A</b>	
11:00 - 12:30	<b>Metastatic Disease</b> Heinz-Peter Schlemmer	Robert Koch Room
11:00 - 11:30	<b>Liver metastases: what the radiologist needs to know</b> - Wolfgang Schima	
11:30 - 12:00	<b>Multiparametric imaging of bone marrow metastatic disease</b> - Anwar Padhani	
12:00 - 12:30	<b>Opportunities and challenges of PET/MR in metastatic disease</b> - Hersh Chandarana	

<b>11.00 - 12.30</b>	<b>Paediatric Tumours</b> Kieran McHugh	<b>Bernhard von Langenbeck Room</b>
11:00 - 11:20	MRI in fetal tumours - Gabriele Masselli	
11:20 - 11:40	Tricky bone tumours - Anne Smets	
11:40 - 12:00	Pancreatic tumours - Alex Towbin	
12:00 - 12:20	Pitfalls in paediatric oncologic imaging - Kieran McHugh	
12:20 - 12:30	Q&A	
<b>12:30 - 14:00</b>	<b>Lunch</b> Parallel Industry Sponsored Symposia. Please see page 25 for details	
<b>14:00 - 15:30</b>	<b>Cases I Would Like to Read Again</b> Stefan Diederich	<b>Main Lecture Hall</b>
14:00 - 14:20	Chest - Christian Herold	
14:20 - 14:40	Liver - Wolfgang Schima	
14:40 - 15:00	Pancreas - Jay Heiken	
15:00 - 15:20	Female Pelvis - Andrea Rockall	
15:20 - 15:30	Q&A	
<b>14:00 - 15:30</b>	<b>Kidney and Adrenal</b> Alberto Vargas & Hersh Chandarana	<b>Robert Koch Room</b>
14:00 - 14:30	Multiparametric imaging of renal tumors - Hersh Chandarana	
14:30 - 15:00	Linking the imaging features of renal disease and their impact on management strategies - Alberto Vargas	
15:00 - 15:30	Imaging workup and management of adrenal incidentalomas - Khaled Elsayes	
<b>14:00 - 15:00</b>	<b>Contrast-Enhanced Ultrasound</b> Olivier Lucidarme	<b>Bernhard von Langenbeck Room</b>
14:00 - 14:30	CEUS of the liver - Olivier Lucidarme	
14:30 - 15:00	CEUS of the pancreas - Mirko D'Onofrio	
<b>15:00 - 16:00</b>	<b>Refreshment Break and Close</b>	

## Coming in 2018

### INTERACTIVE ONE-DAY WORKSHOPS

- Masterclass in the imaging of gynaecological cancers (2nd edition)
- Masterclass in the imaging of hepatobiliary tumours
- Masterclass in the imaging of thoracic neoplasms
- Masterclass in Whole Body MR Imaging (NEW!)

Register your interest on our homepage ([icimagingociety.org.uk](http://icimagingociety.org.uk)), to be kept informed about ICIS teaching courses.

### ICIS 2018

Advancing Cancer Imaging: Improving Patient Outcomes

7th - 9th October 2018 - Palais de l'Europe, Menton, France

# Scientific Papers

## Monday 2nd October 2017

### SCIENTIFIC SESSION 1

🕒 12:30 – 13:00

📍 Robert Koch Room

👤 Rosemarie Forstner and Jurgen Fütterer

**12:30 – 12:40 Dr Iva Petkovska**  
Texture analysis (TA) in the determination of complete tumor response in rectal cancer MRI.

**12:40 – 12:50 Prof Andrea Rockall**  
Malnutrition and sarcopenia: risk factors for shorter survival after pelvic exenteration for recurrent gynecological malignancy.

**12:50 – 13:00 Dr Theresia Sarabhai**  
Comparison of 18F-FDG PET/MRI and MRI for whole-body staging of patients with primary cervical cancer.

### SCIENTIFIC SESSION 2

🕒 12:30 – 13:00

📍 Main Lecture Hall

👤 Giuseppe Petralia and Alex Towbin

**12:30 – 12:40 Prof Alain Rahmouni**  
Whole-Body Diffusion-Weighted Imaging and Iron Deposits in Hodgkin, Follicular and Diffuse Large B-Cell Lymphomas.

**12:40 – 12:50 Ms Katja De Paepe**  
Assessing early treatment response in Hodgkin lymphoma based on texture analysis using whole-body diffusion-weighted imaging.

**12:50 – 13:00 Dr Raphaëla Dresen**  
STIR versus SPAIR fat suppression in WB-DWI/MRI: image quality and artefacts.

## Tuesday 3rd October 2017

### SCIENTIFIC PAPER SESSION 3

🕒 12:30 – 13:00

📍 Robert Koch Room

👤 Evis Sala and Alberto Vargas

**12:30 – 12:40 Dr Ravikanth Balaji**  
Intravoxel incoherent motion diffusion imaging in stage III multiple myeloma before therapy and correlation with histology.

**12:40 – 12:50 Ms Doris Leithner**  
[68Ga] Pentixafor-PET/MRI for CXCR4 imaging of chronic lymphocytic leukemia.

**12:50 – 13:00 Ms Katja De Paepe**  
Whole-body diffusion-weighted MRI after one cycle of immunochemotherapy predicts treatment outcome in aggressive non-Hodgkin lymphoma.

### SCIENTIFIC PAPER SESSION 4

🕒 12:30 – 13:00

📍 Main Lecture Hall

👤 Ann King and Alex Towbin

**12:30 – 12:40 Prof Christina Pfannenber**  
18F-FDG-PET detects complete response to anti-PD1-therapy in melanoma patients two weeks after start of therapy.

**12:40 – 12:50 Mr Kevin Pinto**  
Metastasis in locally-advanced and recurrent breast cancer: Is there any correlation with breast cancer subtype?

**12:50 – 13:00 Mr Helge Kniep**  
MR Radiomics features of brain metastases support primary tumor identification.

# Posters

<b>01</b>	Is there any role for Image guided lung and liver ablation as a method of non-curative cytoreduction?	<b>Simon Smith, Paul Jennings, Zoltan Szucs</b>
<b>02</b>	Cryoablation of pulmonary tumors: procedural and post-procedural imaging features	<b>Lyons GR, Pua BB, Bassik N, Winokur RA, Talenfeld AD, Madoff DC</b>
<b>03</b>	Leiomyosarcoma of the ovarian vein: computed tomography features of a rare disease entity	<b>KY Kwok, CYH Chan, KWS Ko, BCK Chow</b>
<b>04</b>	Incidental pulmonary nodules: 2017 Fleischner Society guidelines	<b>SJ Neville, LE Quint</b>
<b>05</b>	Combination of MR imaging and PET CT in diagnosis and management of pelvic lesions	<b>De Luca S, Grana M F, Alarcón L, Casalini Vañek E, Fernández M, Eyheremendy E P</b>
<b>06</b>	MRI of rectal carcinoma - What the surgeon wants to know?	<b>Krishnan V, Chinchure D</b>
<b>07</b>	Implementing a volunteer sonographer led hospice based ultrasound service – the first three years' experience	<b>J. Eastman, C. Midgley</b>
<b>08</b>	Imaging features of Glomus Jugulare tumour with histopathological correlation	<b>Shankar.KR, Varsha.T, Hazif.B, Sindhu.N, Parthasarathi.A, Pravin.GU</b>
<b>09</b>	Disease and treatment related complications in oncological imaging with 18F-FDG PET/CT	<b>Raghava Kashyap, Kanhaiyalal Agrawal</b>
<b>10</b>	Infrequent primary and secondary pancreatic tumours	<b>Nazar M, De Luca S, Carrera C, Barale C., Castro Cavallo L and Eyheremendy E. P.</b>
<b>11</b>	Thoracic manifestations of breast cancer, its treatment and complications – what the radiologist needs to know	<b>S Bhuva, J Lee</b>
<b>12</b>	Understanding ESTRO– radiological pearls and pitfalls for delineating target volumes for radiotherapy in breast cancer	<b>S Bhuva, J Lee, F Duane, C Taylor, G Andrade</b>


 *Posters continue over the page*

## Posters *continued*

13	Asymptomatic Nasopharyngeal carcinoma: Early detection and assessment of loco-regional extension with imaging	<b>Krishnan V, Shenoy JS</b>
14	Brachial Plexopathy in breast cancer – what the radiologist needs to know	<b>C Goss, E Green, S Bhuva</b>
15	Extra-nodal lymphoma	<b>N Parvizi, S Bhuva, C Johnson, N Taylor, M Subesinghe</b>
16	Various scintigraphic and anatomico-metabolic fusion imaging procedures in diagnosis, theranostics and follow-up of thyroid malignancies	<b>CNB Harisankar</b>
17	Atypical intramural corporal uterine lesion and peritoneal nodules: the added value of Proton MR Spectroscopy	<b>Heming C.A.M., Leite J.A., Zuza D.C., Laterça F.J., Calabria M., Martins, C.L.C.S., Carvalho L.A., Sena B.F.D.P.Q., Scapulatempo H.H., Barbosa I.M.G.A. , Mora P.A.R., Scapulatempo-Neto C., Guitmann G., Jr Coutinho A.C.</b>
18	Dual time point 18-FDG PET-CT in the assessment of pulmonary nodules	<b>De Luca S, Carrera C, Alarcón L, Pascuzzi D, Wirtz M, Eyheremendy E P</b>
19	Imaging review of vaginal pathologies	<b>Walker CM, Johnson CA</b>
20	Ovarian lymphoma, an educational review	<b>Johnson CA, Walker CM, Bhuva S, Subesinghe M, Taylor N</b>
21	Multimodality approach for imaging upper tract urothelial carcinoma (UTUC)	<b>A Mastan, S Suut</b>
22	Tumoural pseudoangiomatous stromal hyperplasia (PASH): radiological features of a rare entity	<b>Khin YT , V Reynolds, TR Shimpi, HT Leung</b>
23	Lung adenocarcinoma: computed tomography features, revised pathology classification and prognosis prediction	<b>Sandomenico F., Pizza S, Rusconi G, De Rosa G., Petrillo A</b>

24	Evolution of PET/CT attenuation and artifacts & factors affecting SUV: corrective measures	<b>Mythri Shankar, Mohan HK, Rajendra Kulkarni</b>
25	Normalised periprostatic fat volume at MRI predicts prostate cancer aggressiveness in patients undergoing radical prostatectomy	<b>N. Dahrán, M. Szewczyk-Bieda, C. Wei, G. Nabi, S. Vinnicom</b>
26	Essentially clinically occult brainstem strokes associated with resection of large cerebellopontine cistern vestibular schwannomas	<b>D. Quint, T. Hollon, L. Savastano, D. Argersinger, B.G. Thompson</b>
27	Whole-Body MRI for cancer screening in asymptomatic subjects; frequency and management of relevant findings	<b>G. Petralia, A.R. Padhani, E. Tagliabue, P. Summers, C. Giorgi, E. Di Taranto, E. Pace, P. Pricolo, F. Zugni, M. Bellomi</b>
28	Comparison of magnetic resonance imaging findings of primary adenocarcinoma and non-adenocarcinomatous malignant tumours of the rectum	<b>N Niyamanon, K Hongsakul, T Tubtawee</b>
29	Positive predictive value of prostatic multiparametric MRI in patients with high PSA levels: Nairobi experience	<b>Mutala TM, Lazaro E, Odhiambo AO, Kimani NM</b>
30	Value of MRI in patients with penile cancer: histopathological correlation	<b>S. Mukhopadhyay, S. Sen, A. Chandra, D. Lingegowda , P. Ghosh</b>
31	Prognostic value of 18FDG PET/CT in patients listed for liver transplantation for hepatocellular carcinoma	<b>Reizine E, Oubaya N, Evangelista E, Luciani A, Mulé S, Rahmouni A, Lerman L, Natella PA, Calderaro J, Laurent A, Duvoux C, Decaens T, Itti E</b>
32	Recurrence in breast cancer: local versus distant relapse related to time-interval and breast cancer sub-type	<b>Pinto K., Bansal J.</b>
33	Diagnostic value of F18-FDG-PET/CT in CUP syndrome: a single-centre retrospective analysis in a private practice	<b>I. Sacarea, J. Müller-Hübenthal, A. Zölllich</b>

# ICIS 2017 Venues






**A** **ICIS Course venue**  
 2nd – 4th October 2017  
 Langenbeck-Virchow-Haus, Luisenstraße 58,  
 10117 Berlin

**Complimentary Drinks**  
 Monday 2nd October 2017  
 17:30, Langenbeck-Virchow-Haus

**B** **17th Course Party**  
 Tuesday 3rd October 2017  
**18:30, on board the 'Alexander von Humboldt'**  
 Barge departs from station Friedrichstraße/Reichstagufer  
 at 18.40. There will be a stopover at 21.15 at the station  
 Märkisches Ufer for those who would like to leave early.  
 The boat trip will end at 22.45 back at the station  
 Friedrichstraße/Reichstagufer.

If you haven't bought a party ticket you may do so at  
 the ICIS desk on Monday morning. Don't miss out!



# Exhibitors & Sponsors



## ICIS

The International Cancer Imaging Society (ICIS) was established to meet the important challenges of advancing imaging in the multidisciplinary management of cancer. The society runs an annual teaching course as well as hands-on computer workshops on prostate, pancreatic, hepatobiliary, gynaecological and thoracic cancers. The ICIS 2018 teaching course will be held from 7th-9th October on the French Riviera in Menton, situated between Monte Carlo and San Remo. The Society journal, Cancer Imaging with an IF of 2.4, is an open access, peer-reviewed journal publishing original articles, as well as reviews and editorials written by international imaging experts with a subspecialty focus on oncology.

The Society is open to all with an interest in cancer imaging. **Join The International Cancer Imaging Society today and membership could be as low as £25.** For three days only, from 2nd to 4th October, ICIS will be offering the members' registration fee discount retrospectively to any delegate who joins onsite. Delegates can receive up to £55 off their membership if they are attending the teaching course for all three days. Please have a chat with a member of the ICIS team at the ICIS registration desk to hear more about ICIS and the benefits of membership.

[icimagingociety.org.uk](http://icimagingociety.org.uk)



## BioMed Central

Cancer Imaging is the official journal of the ICIS and is published by BMC. It is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Cancer Imaging has an international Editorial Board of imaging experts and achieved a 2016 Impact Factor of 2.404 (Journal Citation Reports).

[cancerimagingjournal.biomedcentral.com](http://cancerimagingjournal.biomedcentral.com)



## Bracco

Bracco Imaging S.p.A., part of the Bracco Group, is one of the world's leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs.

Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS) and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology.

The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements.

[braccoimaging.com](http://braccoimaging.com)



## Guerbet

Guerbet is a pioneer in the contrast agents field with over 90 years' of experience and is one of the leaders in medical imaging worldwide. It offers a full range of pharmaceutical products, medical devices and services for X-ray (XR) and Magnetic Resonance Imaging (MRI) scanners and for Interventional Radiology and Theranostics (IRT) to improve the diagnosis and treatment of patients. With 7% of its revenue and more than 200 employees dedicated to R&D, Guerbet invests heavily in research and innovation. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated €776 million in revenue in 2016.

[guerbet.co.uk](http://guerbet.co.uk)

▶ *Exhibitors and Sponsors continue over the page*

## Exhibition information *continued*



### MEDTRON AG

MEDTRON AG is a globally active company in the field of medical engineering. Doctors, hospitals and diagnostic centres place their trust in MEDTRON's contrast medium injectors made in Germany. Our innovative and high-quality injector systems complement all modern methods of examination which can be performed with the help of MRI, CT and angiography.

Our goal is to combine improved diagnostics, patient-friendliness and cost effectiveness. MEDTRON offers a wide range of device-specific and high-quality consumables for its injectors.

[medtron.com](http://medtron.com)



### Siemens Healthineers

Cancer is as individual as patients themselves. A profound understanding of the faceted characteristics and behavior of a tumor demands deep and integrated knowledge among clinical experts collaborating in interdisciplinary teams – a joint effort to empower personalized cancer care. Cancer Care is our term for advanced technologies that help you look closer and see further – along the entire continuum of care Siemens Healthineers Healthcare Cancer Care portfolio empowers you to realize the full potential of your capabilities – enabling you to achieve better outcomes for your patients.

[siemens.com/mri](http://siemens.com/mri)



### The German Radiological Society Deutsche Röntgengesellschaft

The German Radiological Society is one of the most traditional medical specialists. Its mission is the promotion of radiology in medical application, research and teaching. The DRG and its academy promote further/advanced radiological training at the highest level. They support members with cutting edge events on diagnostics and image-guided radiation therapy providing further/advanced training.

[drg.de](http://drg.de)



## Mint Medical

Mint Medical provides software solutions for medical diagnosis, disease staging, therapy planning and standardized therapy response evaluation in clinical routine and research.

Our main product family, mint Lesion™, supports radiologists in assessing the stage of oncologic disease and the effectiveness of a cancer therapy. mint Lesion™ streamlines your daily readings and lets you benefit from instant access to in-depth knowledge about any lesion from various imaging modalities. Furthermore, mint Lesion™ is a dedicated solution to facilitate research in clinical trials.

[mint-medical.com](http://mint-medical.com)



## Beckelmann

Pharmaceutical wholesaler of diagnostics, medical devices and much more...

[beckelmann.de](http://beckelmann.de)



## Roche

Atezolizumab, a PD-L1-Inhibitor is going to be the backbone in Roche's future in cancer immunotherapy. Several trials in early and later state development are evaluating the efficacy of Atezolizumab across indications in combination with e.g. targeted therapies, chemotherapy or radiation. This symposium should raise awareness of the special response patterns of this therapy and support academia in understanding the MoA of this promising approach.

[roche.com](http://roche.com)

▶ *Exhibitors and Sponsors continue over the page*

## Exhibition information *continued*



### Sirtex

Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.

Our innovative technology, SIR-Spheres® microspheres (Yttrium-90 resin beads), was approved in 2002 for use in the treatment of a variety of unresectable liver tumours as well as in hepatocellular carcinoma within the European Union under a CE Mark. SIR-Spheres® Y-90 resin microspheres are presently used at more than 300 institutions in Europe and to date more than 70.000 treatments have been delivered worldwide.

[sirtex.com](http://sirtex.com)



### Medtronic

Medtronic contributes to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health, and extend life.

[medtronic.com](http://medtronic.com)



### GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE Healthcare works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

[gehealthcare.com](http://gehealthcare.com)

## PHILIPS Philips

Royal Philips is a diversified technology company, focused on improving people's lives through meaningful innovation. Our health care business makes up 42% of our global sales revenue.

With a century of history and more than 450 innovative products and services, we are ready to meet today's challenges in healthcare by creating solutions that deliver better care to more people at lower cost.

[philips.com](http://philips.com)

# Notes

# Notes



# ICIS 2017 Social Events & Sponsor Lectures

## ICIS Drinks Reception

- 🕒 Monday 2nd October, 17.30
- 📍 Langenbeck-Virchow Haus, Berlin
- Complimentary*

The welcome reception will take place in the conference venue at 17.30, after the first day of lectures. Get to know your fellow delegates and the ICIS Faculty over wine and light refreshments in the historic foyer and gallery of Langenbeck-Virchow Haus.

## ICIS 17th Course Party

- 🕒 Tuesday 3rd October, 18.30
- 📍 Alexander von Humboldt



**Alexander von Humboldt** barge, pick up point from station Friedrichstraße/Reichstagufer. The cruise leads you through the historical city via Government Quarter, House of the Cultures of the World, Bellevue Palace, Charlottenburg - turn and further via Museum Island, Humboldt Forum, Nicolai Quarter, Mühlendamm Schleuse, Jannowitzbrücke, Eastside Gallery, Mercedes Bent Arena, Oberbaumbrücke, Media Spree with Universal and MTV, Osthafen, Molecule Man and back. There will be a stopover at 21.15 at the station Märkisches Ufer for those who would like to leave early. The boat trip will end at 22.45 back at the station Friedrichstraße/Reichstagufer.

As the sun sets and the city lights up, step on board the "Alexander von Humboldt" barge for this very special ICIS course party. Relax as the boat cruises along the River Spree, past some of Berlin's most iconic sights. Tickets cost €65 which includes a welcome glass of sparkling wine, a three-course buffet dinner, half a bottle of wine, teas & coffees, a live saxophonist and a DJ.

**Please arrive no later than 18.30. We ask that you arrive with plenty of time to spare as the boat's departure time cannot be delayed.**

We will also have the awarding of prizes to our best posters and presenters. Books kindly donated by CRC Press.

This is an event that you won't want to miss! If you have not already booked for the party, tickets are available to purchase during Sunday and Monday at the registration desk for €65 per person.

## Lunch Symposium: Roche Pharma AG

- 🕒 Monday 2nd October, 13.05 to 13.55
- 📍 Main Lecture Hall

**Challenges of a new era: new response criteria in the course of cancer immunotherapy.**

**Chair:** Prof. Mizuki Nishino, Dana-Farber/Harvard Cancer Center, Boston, US

**Lecture:** Evaluation of CT scans of CIT patients: RECIST vs irRECIST/iRECIST

**Speaker:** Prof. Mizuki Nishino, Dana-Farber/Harvard Cancer Center, Boston, US

**Lecture:** Update on cancer immunotherapy

**Speaker:** Dr. med. Martin Wermke, Universitätskrebzentrum, Dresden, Germany

## Lunch Symposium: Dr. Wolf, Beckelmann und Partner GmbH/MEDTRON AG

- 🕒 Monday 2nd October, 13.30 to 14.00
- 📍 Robert Koch Room (Fifth Floor)

**Laparoscopy as diagnostic and therapeutic option for peritoneal metastasis**

**Lecture:** Laparoscopy for the staging

**Speaker:** Prof. Marc A. Reymond University Hospital Tübingen, Germany

**Lecture:** Radiological diagnosis of peritoneal metastases



**Speaker:** Prof. Dr. med. Bernhard Gebauer, Charité, Berlin, Germany

▶ *Sponsor Lectures continue over the page*

# ICIS 2017 Social Events & Sponsor Lecture

## *continued*

### Breakfast Symposium: Mint Medical

-  Tuesday 3rd October 2017, 8.30 - 9.00
-  Robert Koch Room (Fifth Floor)

#### The new iRECIST criteria from the RECIST working group – all you need to know

**Speaker:** PD Dr. Thorsten Persigehl, University Hospital Cologne, Germany

**Content:** Immune-related therapies can show tumour growth from treatment effect rather than true disease progression ("pseudoprogression"). The iRECIST guideline was developed for the use in cancer immunotherapy evaluation. For the first time, iRECIST distinguishes between unconfirmed and confirmed Progressive Disease (iUPD/iCPD).

In this lecture, we will describe the development of iRECIST, highlight its importance for immunotherapies, compare RECIST 1.1 and iRECIST guidelines, and exemplarily illustrate the iRECIST application.

### Lunch Symposium: Medtronic GmbH



-  Tuesday 3rd October 2017, 13.00 - 13.30
-  Main Lecture Hall

#### Microwave ablation of lung tumours

**Speaker:** PD Dr. med. Dag Wormanns, Evangelische Lungenklinik Berlin, Germany

**Content:** Indications for thermal ablation of lung tumours. Different methods for thermal ablation and their applicability in the lung. Practical considerations for microwave ablation of lung tumours. Review of published results. Complications and their management. Conclusions.

### Lunch Symposium: Bracco imaging Spa

-  Tuesday 3rd October 2017, 13.00 to 13.30
-  Robert Koch Room (Fifth Floor)

**Lecture:** Contrast-enhanced MR imaging of cancer: where do we stand?

**Speaker:** Prof. Günther Schneider, University Hospital, Homburg/Saar, Germany

### Lunch Symposium: Siemens Healthineers GmbH

-  Wednesday 4th October, 13.30 - 14.00
-  Main Lecture Hall

#### Next generation imaging solutions for precision oncology

**Lecture:** Motion-robust dynamic contrast enhanced imaging with Compressed GRASP-VIBE

**Speaker:** Dr. Sergios Gatidis, University of Tübingen, Germany

**Lecture:** Whole-Body MRI in the management of metastatic cancer

**Speaker:** Prof. Giuseppe Petralia, European Institute of Oncology, Milan, Italy

### Lunch Symposium: GE Healthcare Buchler GmbH & Co. KG


-  Wednesday 4th October, 13.30 - 14.00
-  Robert Koch Room (Fifth Floor)

#### The risk of CIN in oncologic-hematologic patients undergoing CECT with iodixanol

**Speaker:** Prof. Dr. med. Marius Horger, Bereichsleitung Medizinische Klinik, Universitätsklinikum Tübingen, Germany

## ICIS wishes to thank

Beckelmann, Bracco, Deutsche Röntgengesellschaft, GE Healthcare, Guerbet, MEDTRON, Medtronic, Mint Medical, Philips, Roche, Siemens Healthineers and Sirtex.



# DOTAREM<sup>®</sup>

Gadoteric acid

## NO COMPROMISE in THE DOTAREM WORLD



### Excellent Safety & Optimal Diagnostic Performance

DOTAREM 0.5 mmol/mL solution for injection. **Composition:** For 100 mL of solution: active ingredient: Gadoteric Acid 27.932 g corresponding to DOTA 20.246 g corresponding to gadolinium oxide 9.062 g. **Indications (\*):** Medicinal product for diagnostic use only: Magnetic Resonance Imaging for cerebral and spinal disease, diseases of the vertebral column, and other whole-body pathologies (including angiography). **Posology and method of administration:** The recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg in adults and children. In angiography, depending on the results of the examination being performed, a second injection may be administered during the same session if necessary. Angiography with Gadoteric acid is not recommended in children (0-18 years). In intracranial and spinal MRI, in some exceptional cases, as in the confirmation of isolated metastasis or the detection of leptomeningeal tumours, a second injection of 0.2 mmol/kg may improve tumor characterisation and facilitate therapeutic decision making. For patients with impaired renal function and paediatric population (0-18 years) more than one dose should not be used during a scan, injections should not be repeated unless the interval between injections is at least 7 days. The product must be administered by strict intravenous injection. Depending on the amount of gadoteric acid to be given to the child, it is preferable to use gadoteric acid vials with a single use syringe of a volume adapted to this amount in order to have a better precision of the injected volume. In neonates and infants the required dose should be administered by hand. **Contraindications:** Hypersensitivity to gadoteric acid, to meglumine or to any medicinal products containing gadolinium. **Special warnings and precautions for use:** Dotarem must not be administered by subarachnoid (or epidural) injection. The usual precaution measures for MRI examination should be taken such as exclusion of patients with pacemakers, ferromagnetic vascular clips, infusion pumps, nerve stimulators, cochlear implants or suspected intracorporeal metallic foreign bodies, particularly in the eye. **General particulars corresponding to all gadolinium contrast agents:** All gadolinium based contrast media can cause minor or major hypersensitivity reactions that can be life-threatening. These can occur immediately (within 60 minutes) or be delayed (within 7 days) and are often unpredictable. Because of the risk of major reactions, emergency resuscitation equipment should be available for immediate use. Hypersensitivity reactions can be aggravated in patients on beta-blockers and particularly in the presence of bronchial asthma. These patients may be refractory to standard treatment of hypersensitivity reactions with beta agonists. Impaired renal function: Prior to administration of gadoteric acid, it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests. There have been reports of Nephrogenic Systemic Fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 mL/min/1.73 m<sup>2</sup>). As there is a possibility that NSF may occur with Dotarem, it should only be used in these patients after careful consideration. CNS disorders: As with other contrast agents containing gadolinium, special precautions should be taken in patients with a low seizure threshold. Precautionary measures, e.g. dose monitoring, should be taken. All equipment and drugs necessary to counter any convulsions which may occur must be made ready for use beforehand. Interactions with other medicinal products and other forms of interaction: No

interactions with other medicinal products have been observed. Formal drug interaction studies have not been carried out. **Fertility, pregnancy and lactation:** Gadoteric acid should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteric acid. Continuing or discontinuing breast feeding for a period of 24 hours after administration of gadoteric acid, should be at the discretion of the doctor and lactating mother. **Effects on ability to drive and use machines:** No studies on the effects on the ability to drive and use machines have been performed. Ambulant patients while driving vehicles or operating machinery should take into account that nausea may incidentally occur. **Undesirable effects:** Uncommon (≥1/1000 to <1/100): hypersensitivity, headache, dysgeusia, dizziness, somnolence, paraesthesia (including burning sensation), hypotension, hypertension, nausea, abdominal pain, rash, feeling hot, feeling cold, asthma, injection site reactions (extravasation, pain, discomfort, oedema, inflammation, coldness). Rare (≥1/10 000 to <1/1 000): anxiety, presyncope, eyelid edema, palpitations, sneezing, throat tightness, vomiting, diarrhoea, salivary hypersecretion, urticaria, pruritus, hyperhidrosis, chest pain, chills. Very rare (<1/10 000): anaphylactic reaction, anaphylactoid reaction, agitation, coma, convulsion, syncope, tremor, parosmia, conjunctivitis, ocular hyperaemia, vision blurred, lacrimation increased, tachycardia, cardiac arrest, arrhythmia, bradycardia, flushing, pallor, vasodilatation, hot flush, cough, dyspnoea, nasal congestion, respiratory arrest, bronchospasm, throat irritation, laryngospasm, pharyngeal oedema, dry throat, pulmonary oedema, erythema, angioedema, edema, muscle cramps, muscular weakness, back pain, arthralgia, malaise, chest discomfort, pyrexia, face oedema, injection site necrosis (in case of extravasation), phlebitis superficial, decreased oxygen saturation. **Not known:** nephrogenic systemic fibrosis. **Overdose:** Gadoteric acid can be removed by haemodialysis. However there is no evidence that haemodialysis is suitable for prevention of nephrogenic systemic fibrosis. **Please note:** the peel-off tracking label on the vials or syringes should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used. The dose used should also be recorded. If electronic patient records are used, the name of the product, the batch number and the dose should be entered into the patient record. **Pharmacological properties:** Pharmacotherapeutic group: paramagnetic contrast media for MRI, ATC code: V08CA02. **Presentation (\*):** 5, 10, 15, 20, 60 & 100 mL in vial (glass) and 10, 15 & 20 mL in a pre-filled syringe (glass). **Marketing authorization holder: (\*)** Information: Guerbet - BP 57400 - F-95943 Roissy CDG cedex - FRANCE. Tel: 33 (0)1 45 91 50 00. Date of revision of this document: September 2016.

For current and complete prescribing information refer to the package insert and/or contact your local Guerbet organization. (\*) Indications, presentations and marketing authorization holder may differ from country to country. Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.



In Collaboration with



# Advancing Cancer Imaging: Improving Patient Outcomes

International Cancer Imaging Society Meeting  
& 18<sup>th</sup> Annual Teaching Course

7<sup>th</sup> - 9<sup>th</sup> October 2018

Palais de l'Europe, Menton, France

On the French Riviera between Monte Carlo and San Remo

**President:** Prof. Wim Oyen, London, UK

Supported by:  
French Society of Radiology



For more information about the course and our Society, please visit:

[icimatingsociety.org.uk](http://icimatingsociety.org.uk)